Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 7 (July)

1. Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth.
   Digestion, 71(3): 131-40. [Abstract] [Full-text]
2. Modern diagnosis and treatment of primary eosinophilia.
   Acta Haematol, 114(1): 52-60. [Abstract] [Full-text]
3. Systemic mastocytosis: bone marrow pathology, classification, and current therapies.
   Acta Haematol, 114(1): 41-51. [Abstract] [Full-text]
4. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.
   Acta Haematol, 114(1): 7-25. [Abstract] [Full-text]
5. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
   Lancet Oncol, 6(7): 491-500. [Abstract] [Full-text]
6. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
   Blood, 106(2): 458-63. [Abstract] [Full-text]
7. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
   Blood, 106(2): 721-4. [Abstract] [Full-text]
8. Drug resistance in cancer: principles of emergence and prevention.
   Proc Natl Acad Sci U S A, 102(27): 9714-9. [Abstract] [Full-text]
9. Chronic myeloid leukemia: a model for oncology.
   Ann Hematol, 84(8): 487-97. [Abstract] [Full-text]
10. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
    Clin Cancer Res, 11(13): 4941-7. [Abstract] [Full-text]
11. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.
    Ann Rheum Dis, 64(8): 1126-31. [Abstract] [Full-text]
12. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases.
    Nat Med, 11(7): 731-9. [Abstract] [Full-text]
13. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Leuk Lymphoma, 46(7): 1097-9. [Abstract] [Full-text]
14. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
    Leuk Lymphoma, 46(7): 993-7. [Abstract] [Full-text]
15. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia.
    Leuk Lymphoma, 46(5): 781-4. [Abstract] [Full-text]
16. Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.
    Leuk Lymphoma, 46(5): 663-70. [Abstract] [Full-text]
17. Anterior rectal wall gastrointestinal stromal tumor presenting clinically as prostatic mass.
    Urol Oncol, 23(4): 268-72. [Abstract] [Full-text]
18. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
    Cancer Res, 65(14): 6409-17. [Abstract] [Full-text]
19. Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.
    Leuk Res, 29(9): 1073-7. [Abstract] [Full-text]
20. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
    Br J Haematol, 130(3): 373-81. [Abstract] [Full-text]
21. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
    Cancer Chemother Pharmacol, 56(4): 358-60. [Abstract] [Full-text]
22. Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?
    Expert Opin Investig Drugs, 14(8): 1063-6. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.